Holen Sie sich die Stockscreener-App
10.98
2.40%
-0.27
Handel nachbörslich:
10.82
-0.16
-1.46%
Schlusskurs vom Vortag:
$11.25
Offen:
$11.51
24-Stunden-Volumen:
584.21K
Relative Volume:
1.13
Marktkapitalisierung:
$640.50M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-153.16M
KGV:
-2.9756
EPS:
-3.69
Netto-Cashflow:
$-134.48M
1W Leistung:
+3.98%
1M Leistung:
-10.00%
6M Leistung:
-42.36%
1J Leistung:
-24.01%
1-Tages-Spanne:
$10.73
$11.92
1-Wochen-Bereich:
$10.11
$11.92
52-Wochen-Spanne:
$9.5005
$30.19
Cullinan Therapeutics Inc Stock (CGEM) Company Profile
Firmenname
Cullinan Therapeutics Inc
Sektor
Branche
Telefon
617-410-4650
Adresse
ONE MAIN STREET, CAMBRIDGE
Vergleichen Sie CGEM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CGEM
Cullinan Therapeutics Inc
|
10.98 | 640.50M | 0 | -153.16M | -134.48M | -3.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 113.67B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 74.97B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.50B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.95B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 29.63B | 3.30B | -501.07M | 1.03B | -2.1146 |
Cullinan Therapeutics Inc Stock (CGEM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-05-01 | Eingeleitet | Stifel | Buy |
| 2024-04-15 | Eingeleitet | William Blair | Outperform |
| 2024-02-15 | Eingeleitet | Wedbush | Outperform |
| 2023-06-15 | Eingeleitet | TD Cowen | Outperform |
| 2022-11-21 | Eingeleitet | BTIG Research | Buy |
| 2021-04-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-02-02 | Eingeleitet | Evercore ISI | Outperform |
| 2021-02-02 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2021-02-02 | Eingeleitet | SVB Leerink | Outperform |
| 2021-02-01 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Cullinan Therapeutics Inc Aktie (CGEM) Neueste Nachrichten
Cullinan Therapeutics (NASDAQ:CGEM) Shares Gap Up Following Analyst Upgrade - MarketBeat
HC Wainwright Issues Positive Forecast for Cullinan Therapeutics (NASDAQ:CGEM) Stock Price - MarketBeat
Cullinan Therapeutics to Participate in Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference - GlobeNewswire
Cullinan Therapeutics Reveals Next-Gen Pipeline Details at Major Biotech Conference - StockTitan
Cullinan Therapeutics (NASDAQ:CGEM) Shares Gap Up After Analyst Upgrade - Defense World
Cullinan/Taiho’s Zipalertinib Stands To Benefit From A Clear Market - News & Insights
Cullinan Management Achieves Milestone in Cancer Trial - TipRanks
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Shares Bought by JPMorgan Chase & Co. - Defense World
Cullinan Therapeutics Says Zipalertinib Trial Met Primary Endpoint -January 29, 2025 at 04:38 am EST - Marketscreener.com
Cullinan Reveals Update On REZILIENT1 Trial Data For Zipalertinib In Non-Small Cell Lung Cancer - RTTNews
Game-Changing Lung Cancer Drug Shows Promise: New Hope for EGFR Mutation Patients - StockTitan
Taiho Pharmaceutical, Taiho Oncology, and Cullinan Therapeutics Announce Primary Endpoint Met in Phase 2b Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy - PR Newswire
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Stock Position Decreased by Assenagon Asset Management S.A. - Defense World
Reviewing Repligen (NASDAQ:RGEN) and Cullinan Therapeutics (NASDAQ:CGEM) - Defense World
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives Average Rating of “Buy” from Analysts - Defense World
Cullinan Therapeutics (NASDAQ:CGEM) Hits New 52-Week LowHere's What Happened - MarketBeat
Harbor Capital Advisors Inc. Purchases 9,385 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
Cullinan Therapeutics (NASDAQ:CGEM) Shares Down 7.3%Should You Sell? - MarketBeat
Cullinan Therapeutics’ CLN-978 And Zipalertinib Look Promising In NSCLC (NASDAQ:CGEM) - Seeking Alpha
Cullinan Therapeutics: Casting A Wide Net With Their Pipeline (NASDAQ:CGEM) - Seeking Alpha
Jennifer Michaelson Sells 4,000 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Stock - MarketBeat
Cullinan Therapeutics' chief scientific officer sells shares worth $50,040 - Investing.com
Cullinan Therapeutics (NASDAQ:CGEM) Stock Price Down 5.4%What's Next? - MarketBeat
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Sees Large Growth in Short Interest - Defense World
Cullinan Therapeutics (NASDAQ:CGEM) Shares Gap UpWhat's Next? - MarketBeat
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Sees Significant Increase in Short Interest - MarketBeat
Don't Ignore The Insider Selling In Cullinan Therapeutics - Simply Wall St
Financial Comparison: Genfit (NASDAQ:GNFT) vs. Cullinan Therapeutics (NASDAQ:CGEM) - Defense World
Geode Capital Management LLC Acquires 231,935 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - MarketBeat
Geode Capital Management LLC Buys 231,935 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
Cullinan Therapeutics CEO sells shares worth $99,708 - Investing.com India
Insider Selling: Cullinan Therapeutics, Inc. (NASDAQ:CGEM) CEO Sells 8,400 Shares of Stock - MarketBeat
Cullinan Therapeutics CEO sells shares worth $99,708 By Investing.com - Investing.com South Africa
Cullinan Therapeutics (NASDAQ:CGEM) Shares Down 2.9%Should You Sell? - MarketBeat
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Given Average Recommendation of “Buy” by Analysts - Defense World
Barclays PLC Acquires 51,300 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - MarketBeat
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Given Average Recommendation of "Buy" by Analysts - MarketBeat
Cullinan Therapeutics (NASDAQ:CGEM) Trading 5.6% Higher – Here’s Why - Defense World
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Shares Acquired by State Street Corp - Defense World
State Street Corp Increases Stake in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - MarketBeat
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Insider Sells $53,547.13 in Stock - MarketBeat
Cullinan Therapeutics' chief medical officer sells $52,851 in stock By Investing.com - Investing.com Australia
Cullinan Therapeutics' chief medical officer sells $52,851 in stock - Investing.com
Cullinan Therapeutics chief scientific officer sells $53,547 in stock - Investing.com
Cullinan therapeutics chief legal officer sells $39,729 in stock - Investing.com India
Cullinan Therapeutics chief scientific officer sells $53,547 in stock By Investing.com - Investing.com UK
Cullinan Therapeutics (NASDAQ:CGEM) Stock Price Up 5.6%What's Next? - MarketBeat
Fmr LLC Purchases 19,681 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
Franklin Resources Inc. Sells 252,868 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - MarketBeat
Cullinan Therapeutics (NASDAQ:CGEM) Shares Down 4%Here's Why - MarketBeat
Finanzdaten der Cullinan Therapeutics Inc-Aktie (CGEM)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.49%
0.79%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):